NCCM
GYRE icon

Nine Chapters Capital Management’s Gyre Therapeutics GYRE Stock Holding History

Nine Chapters Capital Management’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-24
Closed -$55K – 1033
2015
Q1 		$55K Sell
24
-52
-68% -$107K ﹤0.01% 924
2014
Q4 		$157K Buy
76
+24
+46% +$46.2K 0.01% 833
2014
Q3 		$104K Buy
52
+18
+53% +$44.5K 0.01% 926
2014
Q2 		$121K Buy
+34
New +$111K 0.01% 868

Other funds holding GYRE

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Nine Chapters Capital Management's GYRE Position: Q2 2015 in Review

Nine Chapters Capital Management sold out of Gyre Therapeutics (GYRE) in Q2 2015, closing a stake of 24 shares — an estimated $55K sold.

Nine Chapters Capital Management first reported a position in GYRE in Q2 2014 and held it in 4 quarters. The position peaked at $157K in Q4 2014. 46 funds tracked by Wall St. Rank hold GYRE as of Q2 2015.

  • Nine Chapters Capital Management reported no remaining Gyre Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Nine Chapters Capital Management sold 24 Gyre Therapeutics shares in Q2 2015, an estimated $55K.
  • Nine Chapters Capital Management first reported a position in Gyre Therapeutics in Q2 2014 and held it in 4 quarters.
  • Nine Chapters Capital Management's Gyre Therapeutics position peaked at $157K in Q4 2014.
  • 46 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2015.

Based on Nine Chapters Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.